NPI: 1306225941 · SANTA MARIA, CA 93455 · Community Health Clinic/Center · NPI assigned 05/28/2015
Authorized official MERLO, BRANDON controls 20+ related entities in our dataset. Read more
| Authorized Official | MERLO, BRANDON (CHIEF FINANCIAL OFFICER) |
| Parent Organization | PACIFIC CENTRAL COAST HEALTH CENTERS |
| NPI Enumeration Date | 05/28/2015 |
Other providers sharing the same authorized official: MERLO, BRANDON
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 2,978 | $96K |
| 2019 | 4,295 | $217K |
| 2020 | 4,432 | $288K |
| 2021 | 4,814 | $384K |
| 2022 | 5,893 | $470K |
| 2023 | 6,761 | $363K |
| 2024 | 3,688 | $200K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 8,348 | 8,062 | $812K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9,350 | 8,977 | $636K |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1,990 | 1,968 | $229K |
| 99051 | 1,843 | 1,781 | $103K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1,241 | 1,220 | $55K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 645 | 638 | $52K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1,356 | 1,338 | $21K |
| 99215 | Prolong outpt/office vis | 124 | 124 | $17K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 428 | 423 | $15K |
| 81025 | 1,346 | 1,324 | $14K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 870 | 861 | $13K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 688 | 656 | $11K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 246 | 245 | $10K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 208 | 204 | $9K |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 48 | 46 | $9K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 47 | 46 | $4K |
| 81002 | 2,017 | 1,965 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 121 | 115 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1,486 | 1,455 | $2K |
| 86308 | 95 | 93 | $458.86 | |
| 69209 | 15 | 12 | $215.05 | |
| 93000 | 12 | 12 | $140.96 | |
| 81003 | 55 | 54 | $135.50 | |
| 82962 | 41 | 40 | $128.21 | |
| 85018 | 12 | 12 | $24.85 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 12 | 12 | $24.08 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 13 | 12 | $16.96 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 109 | 103 | $12.66 |
| 3074F | 56 | 55 | $0.05 | |
| 3078F | 39 | 39 | $0.04 |